CNE Pflegemanagement, Table of Contents CNE Pflegemanagement 2022; 09(06): 12-13DOI: 10.1055/a-1954-7431 Anzeige BTKi-Therapie bei CLL: Die MFA als Förder:innen der Adhärenz Recommend Article Abstract Buy Article Full Text References 1 Wendtner CM. et al. Onkopedia-Leitlinie. Chronische Lymphatische Leukämie (CLL) Online verfügbar unter: Accessed October 25, 2022 at: https://www.onkopedia.com/de/onkopedia/guidelines/chronische-lymphatische-leukaemie-cll/@@guideline/html/index.html 2 Byrd JC, Brown JR, O´Brien S. et al. Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia. N Engl J Med 2014; 371 (03) 213-223 3 Burger J, Tedeschi A, Barr PM. et al. Ibrutinib as initial therapy for patients with chronic lymphocytic leukemia. N Engl J Med 2015; 373 (25) 2425-2437 4 Burger J, Barr P, Robak T. et al. Ibrutinib for first-line treatment of older patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL): a 4-year epience from the RESONATE-2 study. HemaSphere[EHA Abstract PF343]. 2018 5 Woyach JA, Ruppert AS, Heerema NA. et al. Ibrutinib regimens versus chemoimmunotherapy in older patients with untreated CLL. N Engl J Med 2018; 379 (26) 2517-2528 6 Foulon V, Schöffski P, Wolter P. Patient adherence to oral anticancer drugs: an emerging issue in modern oncology. Acta Clin Belg 2011; 66 (02) 85-96 7 Yap AF, Thirumoorthy. Kwan YH. Systematic review of the barriers affecting medication adherence in older adults. Geriatr Gerontol Int 2016; 16 (10) 1093-1101 8 Farris KB, Cadwallader T, Farley J. et al. Implementation of a model integrating primary and oncology pharmacists‘ care for patients taking oral anticancer agents (OAA). Explor Res Clin Soc Pharm 2022; 7: 100163 9 Fachinformation CALQUENCE®, aktueller Stand 10 Fachinformation Imbruvica®, Stand: August 2022 11 Byrd JC, Hillmen P, Ghia P. et al. Acalabrutinib versus ibrutinib in previously treated chronic lymphocytic leukemia: results of the first randomized phase III trial. J Clin Oncol 2021; 39 (31) 3441-3452 12 Spoelstra SL. Why patients prescribed oral agents for cancer need training: a case study. Clin J Oncol Nurs 2015; 19 (3 Suppl): 3-5 13 Randhawa B, Lewis E, Owen C. Treating CLL with Bruton Tyrosine Kinase Inhibitors: The Role of the Outpatient Oncology Nurse. Semin Oncol Nurs 2021; 37 (04) 151177 14 Malin JJ. et al. S1-Leitlinie SARS-CoV-2 Prä-Expositionsprophylaxe. Online verfügbar unter: Accessed November 01, 2022 at: https://www.awmf.org/uploads/tx_szleitlinien/092–002l_S1_SARS-CoV-2_Prae-Expositionsprophylaxe_2022–05_01.pdf 15 Sharman JP, Egyed M, Jurczak W. et al. Acalabrutinib with or without obinutuzumab versus chlorambucil and obinutuzmab for treatment-naive chronic lymphocytic leukaemia (ELEVATE TN): a randomised, controlled, phase 3 trial. Lancet 2020; 395 (10232): 1278-1291 16 Ghia P, Pluta A, Wach M. et al. ASCEND: Phase III, Randomized Trial of Acalabrutinib Versus Idelalisib Plus Rituximab or Bendamustine Plus Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia. J Clin Oncol 2020; 38 (25) 2849-2861 17 Lipsky A, Lamanna N. Managing toxicities of Bruton tyrosine kinase inhibitors. Hematology Am Soc Hematol Educ Program 2020; 1: 336-345
